Loading stock data…
$26.95+0.16 (+0.60%)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Vera Therapeutics, Inc. in the Healthcare sector is trading at $26.95 with a market capitalization of $2.4B. Wall Street consensus targets $74.20 (15 analysts), implying a +175.3% move over the next 12 months. The stock is currently near its 52-week low of $23.05, remaining 29.3% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 13 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$112.49M↑ | -$125.13M↓ | -$94.21M↓ | -$83.93M↓ | -$80.14M |
| Net Income | -$109.47M↑ | -$121.03M↓ | -$91.10M↓ | -$80.29M↓ | -$76.53M |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...